

DNA sequence 489 b.p. atgagaatttcg ... aacacttcttga linear

1/1	atg aga att tcg aaa cca cat ttg aga agt att tcc atc cag tgc tac ttg tgt tta ctt	31/11
Met arg ile ser lys pro his leu arg ser	ile ser ile gin cys tyr leu cys leu leu	
61/21	cta aac agt cat ttt cta act gaa gct ggc att cat gtc ttc att ttg ggc tgt ttc agt	91/31
leu asn ser his phe leu thr glu ala gly	ile his val phe ile leu gly cys phe ser	
121/41	gca ggg ctt cct aaa aca gaa gcc aac tgg gtg aat gta ata agt gat ttg aaa aaa att	151/51
ala gly leu pro lys thr glu ala asn trp val	asn val ile ser asp leu lys lys ile	
181/61	gaa gat ctt att caa tct atg cat att gat gct act tta tat acg gaa agt gat gtt cac	211/71
glu asp leu ile gln ser met his ile asp ala thr leu tyr thr glu ser asp val his		
241/81	ccc agt tgc aaa gta aca gca atg aag tgc ttt ctc ttg gag tta caa gtt att tca ctt	271/91
pro ser cys lys val thr ala met lys cys phe leu leu glu leu gln val ile ser leu		
301/101	gag tcc gga gat gca agt att cat gat aca gta gaa aat ctg atc atc cta gca aac aac	331/111
glu ser gly asp ala ser ile his asp thr val glu asn leu ile ile leu ala asn asn		
361/121	agt ttg tct aat ggg aat gta aca gaa tct gga tgc aaa gaa tgt gag gaa ctg gag	391/131
ser leu ser ser asn gly asn val thr glu ser gly cys lys glu cys glu glu glu		
421/141	gaa aaa aat att aaa gaa ttt ttg gac agt ttt gta cat att gtc gac atg ttc atc aac	451/151
glu lys asn ile lys glu phe leu asp ser phe val his ile val asp met phe ile asn		
481/161	act tct tga (SEQ ID NO:1)	
thr ser opa (SEQ ID NO:2)		

FIG. 1

DNA sequence 489 b.p. atgagaatttcg ... aacacttcttga linear

1/1	atg aga att tcg aaa cca cat ttg aga agt att tcc atc cag tgc tac ttg tgt tta ctt	31/11
Met	arg ile ser lys pro his leu arg ser ile ser ile gin cys tyr leu cys leu leu	
61/21		91/31
cta aac agt cat ttt cta act gaa gct ggc att cat gtc ttc att ttg ggc tgt ttc agt		
leu asn ser his phe leu thr glu ala gly ile his val phe ile leu gly cys phe ser		
121/41		151/51
gca ggg ctt cct aaa aca gaa gcc aac tgg gtg aat gta ata agt gat ttg aaa aaa att		
ala gly leu pro lys thr glu ala asn trp val asn val ile ser asp leu lys lys ile		
181/61		211/71
gaa gat ctt att caa tct atg cat att gat gct act tta tat acg gaa agt gat gtt cac		
glu asp leu ile gln ser met his ile asp ala thr leu tyr thr glu ser asp val his		
241/81		271/91
ccc agt tgc aaa gta aca gca atg aag tgc ttt ctc ttg gag tta caa gtt att tca ctt		
pro ser cys lys val thr ala met lys cys phe leu leu glu leu gln val ile ser leu		
301/101		331/111
gag tcc gga gat gca agt att cat gat aca gta gaa aat ctg atc atc gca aac aac		
glu ser gly asp ala ser ile his asp thr val glu asn leu ile ile leu ala asn asn		
361/121		391/131
agt ttg tct tct aat ggg aat gta aca gaa tct gga tgc aaa gaa tgt gag gaa ctg gag		
ser leu ser ser asn gly asn val thr glu ser gly cys lys glu cys glu leu glu		
421/141		451/151
gaa aaa aat att aaa gaa ttt ttg cag agt ttt gta cat att gtc caa atg ttc atc aac		
glu lys asn ile lys glu phe leu gln ser phe val his ile val gln met phe ile asn		
431/161		
act tct tga (SEQ ID NO:3)		
thr ser opa (SEQ ID NO:4)		

FIG. 2




FIG. 3A




FIG. 3B





FIG. 3C






FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5B




FIG. 5A




FIG. 5C




FIG. 5D






FIG. 5E




Treatment


FIG. 6



Fluorescence Intensity of FcRI/CHO

FIG. 7








FIG. 10

Treatment	1° Allograft Function	MST of Functioning Grafts	n
no-Treatment	40%	6	7
Rapamycin*	50%	12	6
MR1+CTLA4/Fc+ Rapamycin**	75%	30	4
Lytic IL-2/Fc+mIL-15/Fc+ Rapamycin***	100%	>110	5
Non-lytic IL-2/Fc+mIL-15/Fc 50% +Rapamycin***		16	4

- * Rapamycin treatment was initiated 7 day prior to transplantation with 3 mg/kg i.p. daily for 7 days and continued every other day for 4 wks. . DBA2 mice were used as islet allograft donors.
 ** MR1 treatment was administered on day -7, -5, -3, 0 to transplantation at a dose of 0.25 mg i.p. . CTLA4/Fc treatment was administered on day -7, -5, -3, 0 to transplantation at a dose of 0.2 mg i.p. .
 *** IL-2/Fc, and mutant IL-15/Fc treatment was initiated 7 day prior to transplantation for 4 weeks. IL-2/Fc and mutant IL-15/Fc treatment was given at a dose of 5 µg i.p. daily for 4 weeks.

FIG. 11

Tr atment	MST of Functioning Grafts	n
no-Treatment	15	4
Rapamycin*	17	4
Rapamycin + MR1+CTLA4/Fc**	25	4
Rapamycin + Lytic IL-2/Fc ***	22	4
Rapamycin + Lytic mutant IL-15/Fc ***	18	3
Rapamycin + Lytic IL-2/Fc+ mutant IL-15/Fc ***	>60	6

* Rapamycin treatment was initiated at the day of transplantation with 3 mg/kg i.p daily for 7 days and continued every other day for 4 wks. DBA2 mice were used as skin allograft donors.

** MR1 treatment was administrated on day 0, 2, 4, 6 to transplantation at a dose of 0.25 mg i.p. . CTLA4/Fc treatment was administrated on day 0, 2, 4, 6 to transplantation at a dose of 0.2 mg i.p. .

*** IL-2/Fc, and mutant IL-15/Fc treatment was initiated on the day of transplantation with a dose of 5 µg i.p. daily for 4 weeks.

FIG. 12




FIG. 13